GSK beat the numbers, but the real story was the guidance

GSK reported Q4 revenue of £8.6bn, up 8% at constant exchange rates, and core EPS rose 14%, pushing full-year 2025 to the top end of guidance and effectively meeting its 2021–26 medium-term targets a year early. Growth was driven by Specialty Medicines (+18% in the quarter, led by injectable HIV and oncology) and stronger-than-expected vaccine performance (Shingrix, Arexvy), while General Medicines declined; R&D spend increased as oncology assets entered pivotal trials. Management set 2026 sales guidance of 4–6% CER with a material FX headwind, signalled continued capital returns (c. £600m buybacks in H1 and a dividend rising from 66p to guided 70p), and reiterated the longer-term >£40bn 2031 revenue ambition, leaving valuation (c. 12–13x forward vs 15–17x peers) and HIV patent expiry risk as the key investor considerations.

Analysis

Market structure: GSK’s Q4 beat plus specialty medicines growth (+18% in Q4) and vaccines upside (Shingrix, Arexvy) consolidate its position in injectable HIV and oncology niches, increasing pricing power in those subsegments. Management’s conservative 2026 guide of 4–6% (FX headwind baked in) signals room for upside vs consensus near the top of that range; the balance sheet is now funding R&D, dividends (66p->70p) and ~£600m H1 buybacks, tightening free-float and supporting the equity.

Risk assessment: Tail risks include accelerated generic/HIV patent erosion over the next 3–5 years, renewed US pricing regulation, or a CDC-driven demand step-down for vaccines—any of which could remove the re-rating case. Short-term (days–weeks) risks center on FX resets and political headlines; medium-term (3–12 months) risks are trial readouts and guidance refreshes; long-term upside depends on pivotal oncology readouts and how management defends post-patent cash flow.

Trade implications: The asymmetric setup favors being long GSK (LSE:GSK/NYSE:GSK) via equity or limited-cost options for 12–18 months to capture a 20–25% re-rate if specialty momentum continues and guidance is conservatively beaten. Implement pair trades (long GSK / short AZN) to isolate idiosyncratic re-rating potential; use 9–12 month call spreads or sell 8–10% OTM puts for pickup with defined risk.

Contrarian angles: Consensus underestimates management’s willingness to set a low bar and beat later — the market may be underpricing optionality from oncology pivotals and continued buybacks. Conversely, the market may also be underestimating the pace of HIV revenue decline; watch quarterly specialty exit-rate trends and FX-adjusted sales for a decisive signal within 2–3 quarters.

Key Decisions for Investors

• Establish a 2–3% long position in GSK (LSE:GSK/NYSE:GSK) with a 12–18 month horizon; target total return 20–25% and set a tactical stop-loss of 10% or cut if management trims FY26 guidance below 3% sales growth or specialty medicines growth falls below 10% YoY across two consecutive quarters.
• Execute a relative-value pair: go dollar‑neutral long GSK vs short AZN (AstraZeneca) 1:1 to capture a potential 2–4 P/E turn convergence over 6–12 months; exit if the forward P/E spread narrows to ≤1 turn or after 12 months.
• Use options to express upside while limiting cost: buy a 9–12 month GSK call debit spread sized to ~1–2% of portfolio (cap upside at ~20–25% to reduce premium); alternatively sell 3–6 month cash‑secured puts ~8–10% OTM to collect yield if willing to be assigned.
• Reallocate 1–2% from legacy consumer/General Medicines exposures (e.g., HLN-weighted holdings) into specialty-focused biopharma names or GSK, and hedge FX exposure if >30% of your book is GBP/FX sensitive; reassess after Q1 trading updates and any CDC RSV guidance changes within 60–90 days.